12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RG7334: Phase Ib discontinued

BioInvent said partner Roche discontinued a Phase Ib trial evaluating RG7334 plus Nexavar sorafenib in up to 70 patients. According to BioInvent, Roche concluded that slow recruitment in the first part of the trial would make completing the...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >